Bibliography
- Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013;496:504-7
- Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002;185:1213-21
- Whitehorn J, Van Vinh CN, Truong NT, et al. Lovastatin for adult patients with dengue: protocol for a randomised controlled trial. Trials 2012;13:203
- St John AL, Rathore AP, Raghavan B, et al. Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage. Elife 2013;2:e00481
- Lim SP, Wang QY, Noble CG, et al. Ten years of dengue drug discovery: progress and prospects. Antiviral Res 2013;100(2):500-19
- Yin Z, Chen YL, Schul W, et al. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci USA 2009;106:20435-9
- Nguyen NM, Tran CN, Phung LK, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 2013;207:1442-50
- Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine 2011;29:7221-8
- Erbel P, Schiering N, D'Arcy A, et al. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol 2006;13:372-3
- Noble CG, Lim SP, Chen YL, et al. Conformational flexibility of the Dengue virus RNA-dependent RNA polymerase revealed by a complex with an inhibitor. J Virol 2013;87:5291-5
- Wang QY, Bushell S, Qing M, et al. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 2011;85:6548-56
- Xie X, Wang QY, Xu HY, et al. Inhibition of dengue virus by targeting viral NS4B protein. J Virol 2011;85:11183-95
- van Cleef KW, Overheul GJ, Thomassen MC, et al. Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication. Antiviral Res 2013;99:165-71
- Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100
- Byrd CM, Dai D, Grosenbach DW, et al. A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob Agents Chemother 2013;57:15-25